| 摘要: |
| 目的：头孢哌酮舒巴坦钠联合小剂量甲泼尼龙对重症肺炎患儿临床疗效、炎症状态及安全性分析。方法：选取2022年1月至2024年11月以台州市中心医院(台州学院附属医院) 收治的重症肺炎患儿102例，分为T组（头孢哌酮舒巴坦钠组）51例和TJ组（头孢哌酮舒巴坦钠联合小剂量甲泼尼龙）51例。T组进行头孢哌酮舒巴坦钠治疗。TJ组在T组基础上加用小剂量甲泼尼龙治疗。对比临床疗效、临床症状消失时间、炎症指标、安全性。结果：治疗后，TJ组临床有效率高于T组（P＜0.05）；治疗后，临床症状消失时间少于T组（P＜0.05）；治疗后，TJ组C-反应蛋白（CRP）、降钙素原（PCT）、中性粒细胞百分比水平均低于T组（P＜0.05）；治疗过程中，TJ组不良事件发生率21.57%（11/51），T组为15.69%（8/51），差异无意义。结论：头孢哌酮舒巴坦钠联合小剂量甲泼尼龙在重症肺炎患儿治疗中，通过抗菌、抗炎合作的角度，能够有效改善患儿机体内重症肺炎带来的炎症反应，实现减轻患儿临床症状、缩短其治疗周期的效果，且具有较好的安全性，具有临床推广价值。 |
| 关键词: 儿童重症肺炎 头孢哌酮舒巴坦钠 小剂量甲泼尼龙 临床疗效 炎症指标 安全性 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Clinical efficacy, inflammatory status and safety analysis of cefoperazone sulbactam sodium combined with low dose methylprednisolone in children with severe pneumonia |
|
wangjun, caitingting
|
|
Taizhou Central Hospital(Taizhou University Hospital)
|
| Abstract: |
| To analyze the clinical efficacy, inflammatory status and safety of cefoperazone sulbactam sodium combined with low dose methylprednisolone in children with severe pneumonia.Methods: A total of 102 children with severe pneumonia admitted to Taizhou Central Hospital (Affiliated Hospital of Taizhou College) from January 2022 to November 2024 were selected and divided into T group (cefoperazone sulbactam sodium group) (51 cases) and TJ group (cefoperazone sulbactam sodium combined with low-dose methylpredone) (51 cases). Group T was treated with cefoperazone and sulbactam sodiumTJ group was treated with a small dose of methylprednisolone on the basis of T group. The clinical efficacy, duration of clinical symptom resolution, inflammation index and safety were compared. Results: After treatment, the clinical effective rate of TJ group was higher than that of T group (P < 0.05). After treatment, the disappearance time of clinical symptoms was less than that in T group (P < 0.05). After treatment, C-reactive protein (CRP), procalcitonin (PCT) and neutrophil percentage in TJ group were lower than those in T group (P < 0.05). In the course of treatment, the incidence of adverse events was 21.57% (11/51) in group TJ and 15.69% (8/51) in group T, with no significant difference. Conclusion: In the treatment of children with severe pneumonia, cefoperazone and sulbactam sodium combined with low-dose methylprednisolone can effectively improve the inflammation caused by severe pneumonia in the body, reduce clinical symptoms and shorten the treatment cycle of children through the perspective of antibacterial and anti-inflammatory cooperation, and has good safety and clinical promotion value. |
| Key words: child severe pneumonia Cefoperazone sulbactam sodium Low dose methylprednisolone Clinical effect Indicators of inflammation Security |